InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,170.69
(
0.84%
)
US TECH 100
17,564.00
(
0.83%
)
Dow Jones
38,790.65
(
0.30%
)
Brent Oil
83.27
(
0.17%
)
Bitcoin
63,117.09
(
-1.38%
)
Post# of 251728
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: ghmm post# 217440

Thursday, 02/22/2018 1:48:05 PM

Thursday, February 22, 2018 1:48:05 PM

Post# of 251728
QUIZ Answer

@jq1234t got the correct answer UTHR

They have generic risks to their PAH products. I thought they would have been impacted more by Flolan generics (years ago) given at least one had some improved profile. They also have run into delays with their implantable pump (they were working on this implying it was close while I was a shareholder several years ago).

Here is the EP Vantage story JQ linked
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=767394&isEPVantage=yes
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up